A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
暂无分享,去创建一个
T. Yamauchi | K. Tobinai | N. Uike | K. Ando | S. Miyawaki | Takashi Watanabe | T. Hotta | H. Asou | S. Fujisawa | T. Sakura | T. Yokozawa | K. Tsuboi | R. Kihara
[1] J. Schellens,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Jason Clark,et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.
[3] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Yuetsu Tanaka,et al. Retracted: Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV‐1‐infected T lymphocytes in vitro , 2010, International journal of cancer.
[5] K. Venkatakrishnan,et al. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. , 2010 .
[6] J. Blagg,et al. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias , 2010, Leukemia.
[7] M. Furihata,et al. Analysis of Aurora B kinase in non-Hodgkin lymphoma , 2009, Laboratory Investigation.
[8] H. Kantarjian,et al. Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia. , 2009 .
[9] Riccardo Spinelli,et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Suzanne F. Jones,et al. A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[11] J. Fitzgibbon,et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. , 2009, Cancer research.
[12] Mladen Vinković,et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.
[13] Mark A J Chaplain,et al. Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase , 2008, Proceedings of the National Academy of Sciences.
[14] A. Gratwohl,et al. Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies , 2008 .
[15] Suzanne F. Jones,et al. 282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors , 2008 .
[16] R. Advani,et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients , 2008 .
[17] I. Judson,et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours , 2008 .
[18] Suzanne F. Jones,et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results , 2008 .
[19] H. Kantarjian,et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia , 2008 .
[20] K. Mills,et al. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts , 2008, Haematologica.
[21] M. Beeram,et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results , 2007 .
[22] Rajesh Odedra,et al. AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.
[23] E. Estey,et al. Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Lister,et al. The Activity of the Novel Aurora Kinase B Inhibitor AZD1152 in Acute Myeloid Leukaemia Cells. , 2005 .
[25] H. Kawai,et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation , 2005, Oncogene.
[26] Erich A Nigg,et al. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. , 2004, Current opinion in genetics & development.
[27] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Katayama,et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. , 2002, Cancer research.
[29] C. Earle,et al. The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.
[30] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[31] J. Fitzgibbon,et al. AZD 1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo , 2009 .
[32] Bob Löwenberg,et al. Acute myeloid leukemia and acute promyelocytic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.
[33] J. Downing,et al. Acute myeloid leukemia. , 1999, The New England journal of medicine.
[34] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.